Latest News

Title
Programme
28 May 2015 ESMO Press Release: Challenges Ahead for European Clinical Trials
28 May 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Generic Bortezomib Haematologic malignancies - Anticancer agents & Biologic therapy
27 May 2015 The New Global Era of Cancer Research Translational research
27 May 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Dinutiximab Cancer in Special Situations - Cancer Immunology and Immunotherapy
26 May 2015 European Medicines Agency Issues Positive Recommendation for a New Therapeutic Indication for Ibrutinib Haematologic malignancies - Anticancer agents & Biologic therapy
22 May 2015 The European Medicines Agency Recommends Granting a Marketing Authorisation for Pembrolizumab Melanoma - Cancer Immunology and Immunotherapy
22 May 2015 The European Medicines Agency Recommends Granting a Marketing Authorisation for Nivolumab in Squamous NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
22 May 2015 WHO Model List of Essential Medicines Revised Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
20 May 2015 Pembrolizumab Seems to be a New Immune Checkpoint Inhibitor Option for NSCLC, However is our Knowledge on Tumour Biomarkers Enough? Lung and other thoracic tumours
18 May 2015 Annals of Oncology Press Release: World First – Researchers Quantify the Proportion of Different Genetic Mutations Contained within Individual Bowel Cancers Gastrointestinal cancers
12 May 2015 Lower Radiation Doses May Be Sufficient For Treating Certain Cancers, Report IAEA Experts Bioethics, legal and economic issues
08 May 2015 IMPAKT 2015 News: Molecular Screening of Patients with Metastatic Breast Cancer Can Be Carried-Out Across EU Countries Breast cancer - Personalised medicine
07 May 2015 IMPAKT 2015 News: A Circulating Tumour Cell Liquid Biopsy May Be Used for Non-Invasive Mutational Analysis in Patients with Breast Cancer Breast cancer - Translational research
07 May 2015 IMPAKT 2015 News: PI3 Kinase and CDK4/6 Inhibitors Are Highly Active in ER-Positive Breast Cancer Breast cancer - Translational research - Anticancer agents & Biologic therapy